Abstract
Background/Aims: The logopenic variant of primary progressive aphasia (lvPPA) is characterized by impaired word-finding and sentence repetition with phonologic errors but spared motor speech and grammar and semantic knowledge. Although its language deficits have been well studied, the full spectrum of cognitive changes in the lvPPA remains to be defined. We aimed to explore the neurocognitive profile of the lvPPA using a newly developed cognitive screening tool for atypical dementias, the Dépistage Cognitif de Québec (DCQ). Methods: We compared 29 patients with lvPPA to 72 amnestic variant Alzheimer disease (aAD) to 438 healthy control (HC) participants. Performance on the 5 indexes of the DCQ (Memory, Visuospatial, Executive, Language and Behavioral) was compared between the 3 groups. Results: Results showed a significantly lower performance for lvPPA participants in all neurocognitive domains, when compared to HC. When compared to aAD, lvPPA participants had significantly lower scores for language, executive, and visuospatial abilities, but not for memory and behavior. Conclusion: Altogether, these findings better define the neurocognitive changes of lvPPA.
References
1.
Mesulam
M
. Primary progressive aphasia: a dementia of the language network
. Dement Neuropsychol
. 2013
;7
(1
):2
–9
. .2.
Knibb
JA
, Xuereb
JH
, Patterson
K
, Hodges
JR
. Clinical and pathological characterization of progressive aphasia
. Ann Neurol
. 2006
;59
(1
):156
–65
. .3.
Neary
D
, Snowden
JS
, Gustafson
L
, Passant
U
, Stuss
D
, Black
S
, et al Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria
. Neurology
. 1998
;51
(6
):1546
–54
. .4.
Henry
ML
, Gorno-Tempini
ML
. The logopenic variant of primary progressive aphasia
. Curr Opin Neurol
. 2010
;23
(6
):633
. .5.
Mesulam
MM
. Primary progressive aphasia: a language-based dementia
. N Engl J Med
. 2003
;349
(16
):1535
–42
. .6.
Gorno-Tempini
ML
, Hillis
AE
, Weintraub
S
, Kertesz
A
, Mendez
M
, Cappa
SF
, et al Classification of primary progressive aphasia and its variants
. Neurology
. 2011
;76
(11
):1006
–14
. .7.
Rascovsky
K
, Hodges
JR
, Knopman
D
, Mendez
MF
, Kramer
JH
, Neuhaus
J
, et al Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
. Brain
. 2011
;134
(Pt 9
):2456
–77
. .8.
Bonner
MF
, Ash
S
, Grossman
M
. The new classification of primary progressive aphasia into semantic, logopenic, or nonfluent/agrammatic variants
. Curr Neurol Neurosci Rep
. 2010
;10
(6
):484
–90
. .9.
Harris
JM
, Jones
M
. Pathology in primary progressive aphasia syndromes
. Curr Neurol Neurosci Rep
. 2014
;14
(8
):466
. .10.
Giannini
LAA
, Irwin
DJ
, McMillan
CT
, Ash
S
, Rascovsky
K
, Wolk
DA
, et al Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia
. Neurology
. 2017
;88
(24
):2276
–84
. .11.
Henry
ML
, Gorno-Tempini
ML
. The logopenic variant of primary progressive aphasia
. Curr Opin Neurol
. 2010
;23
(6
):633
. .12.
Foxe
DG
, Irish
M
, Hodges
JR
, Piguet
O
. Verbal and visuospatial span in logopenic progressive aphasia and Alzheimer’s disease
. J Int Neuropsychol Soc
. 2013
;19
(3
):247
–53
. .13.
Meyer
AM
, Snider
SF
, Campbell
RE
, Friedman
RB
. Phonological short-term memory in logopenic variant primary progressive aphasia and mild Alzheimer’s disease
. Cortex
. 2015
;71
:183
–9
. .14.
Ahmed
S
, de Jager
CA
, Haigh
AM
, Garrard
P
. Logopenic aphasia in Alzheimer’s disease: clinical variant or clinical feature?
J Neurol Neurosurg Psychiatry
. 2012
;83
(11
):1056
–62
. .15.
Magnin
E
, Chopard
G
, Ferreira
S
, Sylvestre
G
, Dariel
E
, Ryff
I
, et al Initial neuropsychological profile of a series of 20 patients with logopenic variant of primary progressive aphasia
. J Alzheimers Dis
. 2013
;36
(4
):799
–808
. .16.
Leyton
CE
, Savage
S
, Irish
M
, Schubert
S
, Piguet
O
, Ballard
KJ
, et al Verbal repetition in primary progressive aphasia and Alzheimer’s disease
. J Alzheimers Dis
. 2014
;41
(2
):575
–85
. .17.
Wood
JL
, Weintraub
S
, Coventry
C
, Xu
J
, Zhang
H
, Rogalski
E
, et al Montreal cognitive assessment (MoCA) performance and domain-specific index scores in amnestic versus aphasic dementia
. J Int Neuropsychol Soc
. 2020
:1
–5
. .18.
Laforce
R
, Sellami
L
, Bergeron
D
, Paradis
A
, Verret
L
, Fortin
MP
, et al Validation of the dépistage cognitif de québec: a new cognitive screening tool for atypical dementias
. Arch Clin Neuropsychol
. 2018 Feb 1
;33
(1
):57
–65
.19.
Sellami
L
, Meilleur-Durand
S
, Chouinard
AM
, Bergeron
D
, Verret
L
, Poulin
S
, et al The dépistage cognitif de québec: a new clinician’s tool for early recognition of atypical dementia
. Dement Geriatr Cogn Disord
. 2018
;46
(5–6
):310
–21
.20.
Laforce
R
, Verret
L
, Poulin
S
, Fortin
MP
, Houde
M
, Bouchard
RW
. Rémi W Bouchard, a pioneer in behavioural neurology
. Lancet Neurol
. 2017
;16
(5
):344
. .21.
Gauthier
S
, Patterson
C
, Chertkow
H
, Gordon
M
, Herrmann
N
, Rockwood
K
, et al 4th Canadian consensus conference on the diagnosis and treatment of dementia
. Can J Neurol Sci
. 2012
;39
(6 Suppl 5
):S1
–8
. .22.
Scheltens
P
, Leys
D
, Barkhof
F
, Huglo
D
, Weinstein
HC
, Vermersch
P
, et al Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates
. J Neurol Neurosurg Psychiatry
. 1992
;55
(10
):967
–72
.23.
Fazekas
F
, Chawluk
JB
, Alavi
A
, Hurtig
HI
, Zimmerman
RA
. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging
. AJR Am J Roentgenol
. 1987
;149
(2
):351
–6
. .24.
Hughes
CP
, Berg
L
, Danziger
WL
, Coben
LA
, Martin
RL
. A new clinical scale for the staging of dementia
. Br J Psychiatry
. 1982
;140
:566
–72
. .25.
McKhann
GM
, Knopman
DS
, Chertkow
H
, Hyman
BT
, Jack
CR
Jr, Kawas
CH
, et al The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease
. Alzheimers Dement
. 2011
;7
(3
):263
–9
. .26.
Eikelboom
WS
, Janssen
N
, Jiskoot
LC
, van den Berg
E
, Roelofs
A
, Kessels
RPC
. Episodic and working memory function in primary progressive aphasia: a meta-analysis
. Neurosci Biobehav Rev
. 2018
;92
:243
–54
. .27.
Appels
BA
, Scherder
E
. The diagnostic accuracy of dementia-screening instruments with an administration time of 10 to 45 minutes for use in secondary care: a systematic review
. Am J Alzheimers Dis Other Demen
. 2010
;25
(4
):301
. .28.
Macoir
J
, Lavoie
M
, Laforce
R
Jr, Brambati
SM
, Wilson
MA
. Dysexecutive symptoms in primary progressive aphasia: beyond diagnostic criteria
. J Geriatr Psychiatry Neurol
. 2017
;30
(3
):151
–61
. .29.
Harciarek
M
, Cosentino
S
. Language, executive function and social cognition in the diagnosis of frontotemporal dementia syndromes
. Int Rev Psychiatry
. 2013
;25
(2
):178
–96
. .30.
Watson
CL
, Possin
K
, Allen
IE
, Hubbard
HI
, Meyer
M
, Welch
AE
, et al Visuospatial functioning in the primary progressive aphasias
. J Int Neuropsychol Soc
. 2018 Mar
;24
(3
):259
–68
.31.
Magnin
E
, Sylvestre
G
, Lenoir
F
, Dariel
E
, Bonnet
L
, Chopard
G
, et al Logopenic syndrome in posterior cortical atrophy
. J Neurol
. 2013
;260
(2
):528
–33
. .32.
Crutch
SJ
, Lehmann
M
, Warren
JD
, Rohrer
JD
. The language profile of posterior cortical atrophy
. J Neurol Neurosurg Psychiatry
. 2013
;84
(4
):460
–6
. .33.
Rosen
HJ
, Allison
SC
, Ogar
JM
, Amici
S
, Rose
K
, Dronkers
N
, et al Behavioral features in semantic dementia vs other forms of progressive aphasias
. Neurology
. 2006
;67
(10
):1752
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
